- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04220190
RAPA-501 Therapy for ALS
Phase 2/3 Trial of Autologous Hybrid TREG/Th2 Cell (RAPA-501) Therapy for Amyotrophic Lateral Sclerosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, non-randomized, multi-center phase 2/3 study evaluating RAPA-501 T cell therapy in pwALS on an expansion cohort.
After a subject consents to the study, an apheresis procedure will be performed to collect cells to manufacture the investigational product, RAPA-501 T cells. RAPA-501 cells are manufactured ex vivo using epigenetic reprogramming to yield a T cell population that is enriched for a dual anti-inflammatory phenotype based on hybrid TREG and Th2 differentiation. RAPA-501 cells express both the TREG and Th2 transcription factors FOXP3 and GATA3, are enriched for expression of the ATP ectonucleotidase molecules CD39 and CD73, are enriched for the T cell homing molecule CD103, and suppress both effector T cell inflammatory molecules and CNS microglial cell inflammatory molecules.
This study consists of a phase 2/3 expansion cohort that is evaluating RAPA-501 T cell therapy at the dose of 80 x 10EE6 cells per infusion, with up to 4 infusions separated by six weeks between doses (infusion at time 0, and then after week 6, 12, and 18). Study subjects are then followed at the treatment site at 24 weeks and 30 weeks on-study; then, subjects are followed remotely using surveys for two years to capture major clinical events and assess survival. The primary objective in the expansion cohort is to determine the feasibility and safety of the highest established safe dose of RAPA-501 (80 x 10EE6 cells per infusion) in patients with standard-risk ALS (as defining by study entry values of: SVC greater than or equal to 70% of predicted normal; time interval since first ALS symptom, 24 months or less; and ALSFRS-R score between 34 and 45). Secondary study objectives relate to assessing the potential efficacy of RAPA-501 therapy through monitoring of ALSFRS-R scores, SVC values, time to King's stage transition, and survival. To enhance an ability to determine potential efficacy, these parameters will be compared to two comparator arms using machine learning algorithms developed by Origent Data Sciences, namely: (1) a virtual intra-patient control cohort (patient serves as own control); and (2) a comparator arm developed by prognostic mapping to the PRO-ACT database. In addition, secondary study objectives relate to study of pre- and post-therapy blood samples (serum and cells) for markers of inflammation and neurodegeneration.
In the initial phase 1/2 study design, patients received therapy on Cohort 1 (low-dose RAPA-501; 20 x 10EE6 cells per infusion), Cohort 2 (high-dose RAPA-501; 80 x 10EE6 cells per infusion), and Cohort 3A (low-dose RAPA-501 when administered after a 3-day host conditioning regimen consisting of pentostatin plus cyclophosphamide. At the time of study amendment to add the expansion cohort, some patients already enrolled to the phase 1/2 aspect of the trial will continue to receive their initially designated cohort therapy and follow-up evaluation.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Daniel Fowler, M.D. Chief Medical Officer, RAPA Therapeutics, LLC
- Phone Number: (301) 518-3104
- Email: dan@rapatherapeutics.com
Study Contact Backup
- Name: Jennifer Sunga Regulatory Affairs Associate, RAPA Therapeutics, LLC
- Phone Number: (571) 277-4916
- Email: jsunga@rapatherapeutics.com
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Principal Investigator:
- James Berry, M.D.
-
Contact:
- Jacqueline Topping
- Phone Number: 617-643-6036
- Email: JTOPPING@mgh.harvard.edu
-
Contact:
- Lisa Lichtenegger
- Phone Number: 617-643-9005
- Email: llichtenegger@mgh.harvard.edu
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Recruiting
- Hackensack University Medical Center
-
Contact:
- Michele Donato Principal Investigator
- Phone Number: 551-996-5855
- Email: michele.donato@hackensackmeridian.org
-
Principal Investigator:
- Michele Donato, M.D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female patients ≥ 18 years of age.
- Patients with sporadic or familial amyotrophic lateral sclerosis (ALS) diagnosed as laboratory-supported possible, probable, or definite according to World Federation of Neurology El Escorial Criteria.
- . Less than or equal to 24 months since ALS symptom onset.
- Total ALSFRS-R score between 34 and 45.
- Must have a source of autologous T cells potentially sufficient to manufacture RAPA-501 cells, as defined by a peripheral CD3+ T cell count ≥ 500 cells per μl.
- Patients may continue riluzole (Rilutek®), and/or edaravone (Radicava®), and/or sodium phenylbutyrate/taurusodial (Relyvrio™) if on a stable dose for at least 30 days prior to the screening visit.
- Patients must be ≥ 2 two weeks removed from major surgery or investigational therapy.
- Patients must have recovered from clinical toxicities ([resolution of CTCAE(v5) [version 5] toxicity to a value of ≤ 2].).
- Serum creatinine ≤ less than or equal to 2.0 mg/dL.
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN).
- Bilirubin ≤ 1.5 (except if due to Gilbert's disease).
- Pulmonary slow vital capacity (SVC) ≥ 70% of predicted normal.
- No history of abnormal bleeding tendency.
- Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient participant at any time without prejudice to future medical care.
Exclusion Criteria:
- Active uncontrolled infection.
- Hypertension not adequately controlled by ≤ 3 medications.
- History of documented pulmonary embolus within 6 months of enrollment.
- Clinically significant cardiac pathology, as defined by: myocardial infarction within 6 months prior to enrollment, Class III or IV heart failure according to NYHA, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
- Patients with history of coronary artery bypass grafting or angioplasty will receive a cardiology evaluation and be considered on a case-by-case basis.
- HIV, hepatitis B, or hepatitis C seropositive.
- Pregnancy or breastfeeding patients.
- Patients of Subjects of childbearing age, or males who have a partner of childbearing potential, who are unwilling to practice contraception.
- Patients Subjects may be excluded at the Principal Investigator discretion of the PI or if it is deemed that allowing participation would represent an unacceptable medical or psychiatric risk.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 2/3 Expansion Cohort, Single-agent RAPA-501 T cells
80 x 10^6 cells per infusion (no host conditioning)
|
TREG/Th2 cells
Other Names:
|
Experimental: Phase 1/2 Only, Single-agent RAPA-501 T cells (dose level Arm 1)
Dose level 1 is 20 x 10^6 cells/infusion
|
TREG/Th2 cells
Other Names:
|
Experimental: : Phase 1/2 Only, Single-agent RAPA-501 T cells (dose level Arm 2)
Dose level 2 is 80 x 10^6 cells/infusion
|
TREG/Th2 cells
Other Names:
|
Experimental: Phase 1/2 Only, RAPA-501 + PC Regimen (Arm 3A)
RAPA-501 T cell therapy preceded by the 3-day pentostatin-cyclophosphamide (PC) regimen
|
TREG/Th2 cells
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
In the expansion cohort enrolling standard-risk pwALS, determine the feasibility and safety of the highest established safe dose of RAPA-501 (80 x 10^6 cells per infusion).
Time Frame: Through 30 Weeks On-Study
|
Through 30 Weeks On-Study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterize immune system parameters pre- and post-therapy.
Time Frame: Through 30 Weeks On-Study
|
Specifically, relative to pretreatment patient peripheral blood values, determine whether study interventions: (a) increase circulating Th2 and TREG cells; (b) reduce circulating Th1 cells; (c) increase T cell expression of programmed death-1 (PD-1); and (d) reduce inflammatory cytokines IL-1-beta, IL-6, and TNF-alpha.
|
Through 30 Weeks On-Study
|
Relative to pretreatment values, characterize the potential effect of RAPA-501 therapy on serum markers of neurodegeneration (neurofilament light, NfL).
Time Frame: Through 30 Weeks On-Study
|
Through 30 Weeks On-Study
|
|
Relative to pretreatment values, characterize the potential effect of RAPA-501 therapy on pulmonary function, as measured by slow vital capacity measurements (SVC, percent of predicted normal).
Time Frame: Through 30 Weeks On-Study
|
Through 30 Weeks On-Study
|
|
Relative to pretreatment values, characterize the potential effect of RAPA-501 therapy on hand grip strength using hand-held dynamometry.
Time Frame: Through 30 Weeks On-Study
|
Through 30 Weeks On-Study
|
|
Using a virtual control cohort and prognostic matching comparator arm (Origent algorithm), determine the potential effect of RAPA-501 therapy on disease progression (ALSFRS-R), pulmonary function (SVC), time to King's stage transition, and survival.
Time Frame: Through 2 Years and 30 Weeks On-Study
|
Through 2 Years and 30 Weeks On-Study
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cerebrospinal fluid assessment
Time Frame: Six months after treatment initiation.
|
To assess cerebrospinal fluid pre- and post- therapy for content of inflammation molecules and neurodegeneration molecules.
|
Six months after treatment initiation.
|
Neuroinflammation assessment
Time Frame: Six months after treatment initiation.
|
Assess neuroinflammation in vivo using PET scan that incorporates a translocator protein radiotracer.
|
Six months after treatment initiation.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Daniel Fowler, M.D., Rapa Therapeutics LLC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RAPA-501-ALS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis
-
Washington University School of MedicineMassachusetts General HospitalSuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, SporadicUnited States
-
University of Sao Paulo General HospitalPontifícia Universidade Católica do ParanáUnknownAMYOTROPHIC LATERAL SCLEROSISBrazil
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
-
CytokineticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States, Netherlands, Canada, Belgium, United Kingdom, France, Germany, Ireland, Italy, Portugal, Spain
-
Columbia UniversityALS AssociationTerminatedAmyotrophic Lateral Sclerosis (ALS)United States
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedAmyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, SporadicMexico
-
University Hospital, GenevaCompletedAmyotrophic Lateral Sclerosis 11Switzerland
-
Fondazione Don Carlo Gnocchi OnlusFondazione Salvatore MaugeriCompleted
Clinical Trials on RAPA-501 Autologous T cells
-
Rapa Therapeutics LLCMassachusetts General Hospital; Hackensack Meridian HealthAvailable
-
Rapa Therapeutics LLCMedical College of WisconsinRecruitingRelapsed, Refractory Multiple MyelomaUnited States
-
Rapa Therapeutics LLCHackensack Meridian HealthTerminated
-
Bellicum PharmaceuticalsActive, not recruiting
-
Bellicum PharmaceuticalsActive, not recruitingStudy of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell TransplantLymphoma, Non-Hodgkin | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Anemia, Aplastic | Primary Immune Deficiency Disorder | Cytopenia | Osteopetrosis | Leukemia, Acute Myeloid (AML), Child | Hemoglobinopathy in ChildrenUnited States
-
University of PennsylvaniaCompleted
-
The First Affiliated Hospital of Nanchang UniversityUnknownRelapsed or Refractory Multiple MyelomaChina
-
Hebei Senlang Biotechnology Inc., Ltd.Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei HospitalRecruitingLymphoma | Leukemia | Multiple Myeloma of Bone (Diagnosis)China
-
The Nordic Network For Clinical Islet TransplantationActive, not recruiting